Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.81 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.81 |
| ▸ | RICTOR | Q6R327 | 3/20 | 0.55 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.55 |
| ▸ | MAPKAP1 | Q9BPZ7 | 3/20 | 0.55 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748722 | 0.90 | MTOR (1.00) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL20692920 | 0.87 | MTOR (0.61) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL21375688 | 0.85 | MTOR (0.74) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL21354081 | 0.84 | MTOR (0.75) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL24055182 | 0.83 | MTOR (0.56) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL17748629 | 0.78 | MTOR (1.00) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL21393938 | 0.78 | MTOR (0.75) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL17748729 | 0.77 | MTOR (0.85) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL23505793 | 0.77 | MTOR (0.85) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL29564081 | 0.77 | MTOR (0.85) | MTORPIK3CARICTORRPTORMAPKAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2022-05-05 | — | — | US | disclosed |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | UNIVERSITÄT BASEL (CH) | 2021-11-30 | — | — | US | disclosed |
| US-10993947-B2 | Treatment of skin lesions | TORQUR (CH) | 2021-05-04 | — | — | US | disclosed |
| US-20210107913-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2020-09-03 | — | — | US | disclosed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885RICTOR 31/4885 |
| US-20210107913-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CBR3, CXCR3 | MTOR 2897/4885PIK3CA 3974/4885RICTOR 2628/4885 |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | MTOR 4473/4885PIK3CA 4513/4885RICTOR 4018/4885 |
| US-10993947-B2 | Treatment of skin lesions | CXCR3, CCR3, C3AR1 | MTOR 4107/4885PIK3CA 3971/4885RICTOR 4301/4885 |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CCR3, CBR3 | MTOR 3212/4885PIK3CA 4158/4885RICTOR 2879/4885 |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885RICTOR 31/4885 |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | CXCR3, CCR3, C3AR1 | MTOR 4107/4885PIK3CA 3971/4885RICTOR 4301/4885 |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885RICTOR 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.